On Nov 9, 2021 Ligand Pharmaceuticals $LGND announced it is pursuing plans to split Ligand into two separate, publicly traded companies with one featuring the OmniAb business bit.ly/3JRDSCV
Here are the Insiders that made it to the Top 5 purchases!
🧵⬇️
1. President and CEO Jacob Chacko acquired 350,000 shares of ORIC Pharmaceuticals $ORIC, a biotech company, paying $4.92 per share for a total amount of $1.72 million. insidearbitrage.com/symbol-metrics…
ORIC Pharmaceuticals $ORIC appointed Jacob Chacko as Chief Executive Officer on May 7, 2018. Prior to this, Jacob was an investor at TPG Capital and he was the CFO of Ignyta, a NASDAQ-listed precision oncology company acquired by Roche in February 2018.
Director Andrew M. Cohn acquired 36,667 shares of $GWRS, paying $16.00 per share for a total amount of $586,672. Mr. Cohn increased his stake by 1.92% to 1.95 million shares with this purchase.